HighTower Advisors’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History

HighTower Advisors’s Portfolio IDNA Stock Details IDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.13M	Buy	+50,255	New	+$1.84M	﹤0.01%	1762

Other funds holding IDNA

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.87B AUM 19.94% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Trek Financial Scottsdale, Arizona $2.16B AUM 42.56% 1-Year Est. Return

Great Diamond Partners Portland, Maine $596M AUM 19.61% 1-Year Est. Return

Lido Advisors Los Angeles, California $39.1B AUM 20.96% 1-Year Est. Return

Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return

Clearwater Capital Advisors Hoffman Estates, Illinois $1.39B AUM 12.56% 1-Year Est. Return

Avior Wealth Management Omaha, Nebraska $3.79B AUM 15.36% 1-Year Est. Return

HighTower Advisors's IDNA Position: Q3 2026 in Review

HighTower Advisors opened a new position in iShares Genomics Immunology and Healthcare ETF (IDNA) in Q3 2026: 50,255 shares worth $2.13M. The stake represents ﹤0.01% of the portfolio and ranks #1762 among its holdings.

44 funds tracked by Wall St. Rank hold IDNA as of Q3 2026.

HighTower Advisors held 50,255 shares of iShares Genomics Immunology and Healthcare ETF worth $2.13M as of Q3 2026.
iShares Genomics Immunology and Healthcare ETF was a new HighTower Advisors position in Q3 2026.
iShares Genomics Immunology and Healthcare ETF made up ﹤0.01% of HighTower Advisors's portfolio in Q3 2026, its #1762 holding.
44 funds tracked by Wall St. Rank held iShares Genomics Immunology and Healthcare ETF as of Q3 2026.

Based on HighTower Advisors's 13F filing for Q3 2026, filed 10 Nov 2026.